DYRUPEG
Live / Registered — Registered (as of 02 Dec 2025)
What this means for you
Registered since 02 Dec 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99299946
- Registration number
- 8052196
- Mark type
- Stylized text
- Filed
- 23 Jul 2025
- Published for opposition
- 14 Oct 2025
- Registered
- 02 Dec 2025
- Attorney of record
- Joseph G. Chu
Goods and services
- Class 005 — Pharmaceuticals: Medicinal preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of injectable pharmaceutical solutions; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of biopharmaceutical preparations; Pharmaceutical preparations for use in reducing the duration and incidence of neutropenia and febrile neutropenia, reducing the chance of infection in people who have certain types of cancer and are receiving chemotherapy medications that may decrease the number of neutrophils, and stimulating white blood cell production, namely, in the form of biopharmaceutical preparations and substances, namely, polypeptides, proteins, and monoclonal antibodies
Owner
- CURATEQ BIOLOGICS PRIVATE LIMITED, HYDERABAD KNOWLEDGE CITY, IN
- CURATEQ BIOLOGICS PRIVATE LIMITED, HYDERABAD KNOWLEDGE CITY, IN
- CURATEQ BIOLOGICS PRIVATE LIMITED, HYDERABAD KNOWLEDGE CITY, IN
Prosecution history
- 02 Dec 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 02 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 14 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Oct 2025 — PUBLISHED FOR OPPOSITION
- 08 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 16 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 Sept 2025 — ASSIGNED TO EXAMINER
- 23 Jul 2025 — APPLICATION FILING RECEIPT MAILED
- 23 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 23 Jul 2025 — NEW APPLICATION ENTERED